8 results about "Norvaline" patented technology

Prodrugs of glutamine analogs are disclosed, such as the prodrugs of aza-serine and 6-diazo-5-oxo-norleucine (DON) and 5-diazo-4-oxo-L-norvaline (L-DONV).

The invention belongs to the technical field of microorganisms and fermentation engineering, and particularly relates to an escherichia coli engineering strain with high yield of L-norvaline as well as a construction method and application of the escherichia coli engineering strain. According to the invention, a common mode microorganism escherichia coli is used as an original strain, and the high yield of L-norvaline by the escherichia coli engineering strain is realized by modifying the metabolic pathway of the escherichia coli engineering strain. A series of metabolic engineering modifications on an original strain comprise knocking out a series of alcohol dehydrogenase and aldehyde dehydrogenase to weaken an endogenous propionaldehyde metabolic pathway of escherichia coli; then, the escherichia coli engineering strain for producing the L-norvaline is obtained by introducing a biosynthesis route of the L-norvaline, and the escherichia coli engineering strain can be used for efficiently producing the L-norvaline in a whole-cell catalysis manner by taking cheap propionaldehyde, glycine and sodium formate as substrates, so that the engineering strain has considerable application value and prospect.

This invention discloses a composition for enhancing oral umami perception and its application, belonging to the fields of food science and oral care technology. This composition amplifies umami signals in food by modulating the oral microenvironment of the user, mimicking the salivary biochemical characteristics of individuals with high umami sensitivity (UTS). The composition contains at least one active ingredient, preferably including: a) an umami perception enhancer, represented by valine, valine, cysteine, arginine, or glycine; and optionally including: b) a taste desensitization inhibitor, such as food-grade nitrates or cyclodextrins; c) an ionic environment modifier, such as calcium chloride or potassium phosphate; and d) a rheological property modifier, such as xanthan gum. This invention provides a novel umami enhancement technology pathway that, by improving taste perception efficiency rather than increasing additive dosage, maintains food flavor while possessing significant public health value.

A solid supplement composition comprising at least one non-ester nitrate compound and at least one isolated amino acid compound, wherein the at least one isolated amino acid compound is norvaline, wherein the at least one isolated amino acid compound is a separate compound than the at least one non-ester nitrate compound, and wherein the solid supplement composition comprises an amount of nitrate ion (NO3−) that is at least about 0.05625 mg. A semisolid supplement composition comprising at least one non-ester nitrate compound and at least one isolated amino acid compound, wherein the at least one isolated amino acid compound is norvaline, wherein the at least one isolated amino acid compound is a separate compound than the at least one non-ester nitrate compound, and wherein the semisolid supplement composition comprises an amount of nitrate ion (NO3−) that is at least about 0.05625 mg.

In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to unit dose compositions comprising (a) L-ornithine or a pharmaceutically acceptable salt thereof; (b) L-norvaline or a pharmaceutically acceptable salt thereof; (c) agmatine or a pharmaceutically acceptable salt thereof; and (d) at least one of the following components: tongkat ali, Tribulus terrestris, horny goat weed, Panax notoginsing, maca root, lycopene, ashwagandha, or any combination thereof. In one aspect, the unit dose compositions can increase or enhance blood flow in a subject. In another aspect, the unit dose compositions can treat erectile dysfunction in a subject.

The invention belongs to the technical field of biology, and particularly discloses yarrowia lipolytica ILV6 protein mutants and application thereof. The ILV6 protein mutant is obtained by mutating the 81st glycine (Gly) of the amino acid sequence of the ILV6 protein of wild type yarrowia lipolytica. The method comprises the following steps: transforming a yarrowia lipolytica ILV6 protein mutant into a yarrowia lipolytica yeast to construct a yarrowia lipolytica recombinant strain; compared with the Yarrowia lipolytica recombinant engineering bacteria which do not express the Yarrowia lipolytica ILV6 protein mutant or express the wild type ILV6 protein or express the saccharomyces cerevisiae wild type ILV6 protein, the Yarrowia lipolytica recombinant engineering bacteria which express the Yarrowia lipolytica ILV6 protein mutant can tolerate DL-norvaline with relatively high concentration; in addition, the content of intracellular valine in the fermentation process can be obviously improved.

This invention relates to the fields of fluorescent contrast agents, radiopharmaceuticals, and nuclear medicine, specifically disclosing the application of a peptide TP-6 ​​in the preparation of tumor diagnostic and / or therapeutic reagents. The peptide TP-6 ​​is: D-Arg-L-Lys-L-Asp-L-Nva-D-Tyr, where D represents a non-natural D-type amino acid, L represents a natural L-type amino acid, and Nva is valine. The molecular probe constructed from the peptide TP-6 ​​of this invention can specifically target tumor sites and exhibits good uptake and retention capabilities at the tumor site, possessing a high target / non-target ratio. It is suitable for preparing intraoperative image-guided tumor diagnostic reagents and radiopharmaceuticals for tumor nuclear medicine diagnosis and precision radiotherapy.

The present invention relates to a polyamino acid nanoparticle with lung targeting, and its preparation method and application. The polyamino acid nanoparticle of the present invention comprises inorganic nanoparticles and a polyamino acid modified on the surface of the inorganic nanoparticle; the polyamino acid comprises a first amino acid residue and a second amino acid residue; the first amino acid residue is a glutamic acid residue; the second amino acid residue comprises one or more of a valine residue, an isoleucine residue, a tryptophan residue, a norvaline residue, and a leucine residue. The present invention clarifies the relationship between structural parameters and lung targeting behavior by regulating the size and type of inorganic nanoparticles, the proportion of polyamino acids, and the feed ratio of reaction raw materials. The polyamino acid nanoparticles with lung targeting properties of the present invention can relieve lung inflammation and treat acute lung injury.